Background: Two prospective randomized trauma trials have shown recombinant factor VIIa (rFVIIa) to be safe and to decrease transfusion requirements. rFVIIa is presently used in 22% of massively transfused civilian trauma patients. The US Military has used rFVIIa in combat trauma patients for five years, and two small studies of massively transfused patients described an association with improved outcomes. This study was undertaken to assess how deployed physicians are using rFVIIa and its impact on casualty outcomes. Methods: US combat casualties (n ϭ 2,050) receiving any blood transfusion from 2003 to 2009 were reviewed to compare patients receiving rFVIIa (n ϭ 506) with those who did not (n ϭ 1,544). Propensity-score matching (primary analysis) and multivariable logistic regression were used to compare outcomes. Differences were determined at p Ͻ 0.05. Results: Twenty-five percent of patients received rFVIIa. Significant differences were noted between groups in indices of injury severity (Injury Severity Score, Abbreviated Injury Scale score, and Glasgow Coma Scale score), admission physiology (systolic blood pressure, diastolic blood pressure, heart rate, temperature, base deficit, hemoglobin, and international normalization ratio), and use of blood products, indicating that patients treated with rFVIIa were more severely injured, in shock, and coagulopathic. For propensity-score matching, factors associated with death were used: Injury Severity Score, Glasgow Coma Scale score, heart rate, systolic blood pressure, diastolic blood pressure, Hgb, and total packed red blood cell. A total of 266 patients per group were matched; 52% of the rFVIIa group. After pairing, there were no significant differences in any of the demographics, including incidence of massive transfusion (53% vs. 51%). There was no difference in the rate of complications (21% vs. 21%) or mortality (14% vs. 20%) for patients not treated or receiving rFVIIa, respectively. Conclusion: In military casualties, rFVIIa is used in the most severely injured patients based on physician selection rather than on guideline criteria. Use of rFVIIa is not associated with an improvement in survival or an
A predominant cause of potentially preventable deaths of military and civilian casualties is hemorrhage. It is the reported cause of death in Ͼ80% of combat casualties both before and after admission to a medical treatment facility. 1, 2 For civilian patients, the in-hospital mortality rate caused by hemorrhage is 26% to 39%. 3, 4 These military and civilian patients die predominantly of noncompressible uncontrolled hemorrhage attributed to injuries to the thorax or abdomen. 5, 6 In addition, many of these patients have concomitant coagulopathy. Rates of coagulopathy at admission for military and civilian patients are 38% and 25% to 28%, respectively. [7] [8] [9] In the presence of uncontrolled bleeding and coagulopathy, damage control resuscitation (DCR) has been advocated. 10 -12 Major tenets of this clinical practice guideline are early control of bleeding and correction of coagulopathy.
One portion of the US military DCR guidelines advocates consideration of the use of recombinant factor VIIa (rFVIIa) to address early coagulopathy and decrease death from hemorrhage. Similar guidelines were promulgated by civilian care providers. 13, 14 More than 75% of the US Level I trauma centers recommended the use of rFVIIa in their massive transfusion protocols 15, 16 based on an early randomized control trial demonstrating a decrease in blood requirements in patients with blunt injuries and an absence of major adverse events. 17 The early finding of a decrease in blood transfusions was recently confirmed in another randomized control trial (Hauser et al., submitted for publication). The US military also recommended the use of rFVIIa in patients requiring a massive transfusion because, early in the present conflicts, the full complement of blood components was not available, which required the use of alternative hemostatic strategies. 18, 19 In the following years, a number of studies were undertaken on the efficacy and safety of rFVIIa in the care of the patients with traumatic injuries. However, no study was definitive as to the efficacy of rFVIIa in this
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Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, 20 -22 In studies of patients with combat-related injuries, a decrease in packed red blood cell (PRBC) requirements was noted in massively transfused patients who received rFVIIa early in the course of their resuscitation. 23 In a follow-on study of a similar patient population, a decrease in mortality was suggested with the early use of rFVIIa, with no increased risk of thrombotic events reported. 24 For these reasons, the military and some civilian centers have continued to provide access to rFVIIa for use in patients with hemorrhagic shock and anticipated to require a massive transfusion or have bleeding refractory to standard treatment. Starting in 2006, we began systematic monitoring of blood component use in the treatment of US military casualties through the Joint Theater Trauma Registry (JTTR). 6, 9, 25 Use of rFVIIa as part of DCR was tracked. The purpose of this study was to assess in which military casualties rFVIIa was used in relation to the promulgated clinical practice guideline and the effectiveness and complication rates of its use.
PATIENTS AND METHODS
The JTTR collects data on patients treated in US military care facilities during the overseas contingency operations. 26 5 If outcome or time of death was not known or the patient died within 17 minutes of admission, the patient was excluded. The exclusion criteria were based on the first death noted to have received rFVIIa, thus limiting survival bias. 27 Data access was approved by the institutional review board at Brooke Army Medical Center.
The clinical practice guideline approved in theaters of combat suggests that rFVIIa use should be considered for administration to trauma patients or patients in shock who have major signs of hemorrhage based on established criteria ( 
Statistical Analysis
Admission characteristics, transfusion of blood products, and outcomes were compared between patients treated with rFVIIa and those who did not receive the drug. Data were analyzed for normality using a Kolmogorov-Smirnov test. Student's t test or Mann-Whitney U test was used to compare differences, as appropriate. Continuous data are presented as median (interquartile range). For dichotomous data, 2 or Fisher's exact test was used, as appropriate, to compare between groups. Kaplan-Meier log-rank test was used to compare unadjusted overall survival. Statistical significance was set at a p Ͻ 0.05 for all group comparisons, and specific p values are presented in the text.
In a second analysis, a multivariate survival analysis was conducted of all patients included in the study, and adjustments made for known confounders. A univariate logistic regression of admission variables and rFVIIa treatment was performed with mortality as the dependent variable. Variables with p Ͻ 0.20 on univariate analysis were included in the final model, where a multivariate logistic regression model was used to examine overall mortality. The logistic regression model was assessed using the area under the receiver operating characteristic (ROC) curve.
We calculated the propensity for treatment with rFVIIa on the basis of variables associated with mortality available for inclusion of the largest number of subjects. We matched each patient in the rFVIIa group to a patient who did not receive the drug and who had the closest propensity score using a standard greedy-matching algorithm.
RESULTS
Between October 2003 and June 2009, a total of 18,638 trauma records for US military casualties were entered into the JTTR. There were 2,101 (11.3%) patients who received at least 1 unit of blood. There were 5 (1%) patients who received rFVIIa and 46 (3%) who did not that met the exclusion criteria. Thus, the final number of patients studied was 2,050. There were 506 (25%) patients who received rFVIIa and 1,544 who did not. Review of the criteria for use of rFVIIa showed a significantly greater incidence of positive criteria in those patients receiving treatment (Table 2) . However, there were still a significant number of patients (Ͼ69%) who met one or more criteria for use and did not receive rFVIIa. This lack of treatment based on guideline criteria suggests that either clinician judgment was used with the preference being independent of guideline criteria or rFVIIa was unavailable.
Patients who received rFVIIa were more severely injured than those who did not receive it. There was a greater incidence of ISS Ͼ15 (82% vs. 54%, p Ͻ 0.0001) and of the need for a massive transfusion (Ն10 units of PRBC in 24 hours; 66% vs. 27%, p Ͻ 0.0001). Treated patients also had a greater incidence of severe injury (Abbreviated Injury Scale score Ն3) to the thorax, abdomen, and head (Table 3 ). There was a similar incidence of patients with an ISS of 75 (1.1% vs. 1.0%). The majority of physiologic variables were significantly different between populations at admission (Table 4) . Subsequently, those patients treated with rFVIIa required more blood components ( Table 5 ). The rate of complications (26% vs. 15%, p Ͻ 0.0001) increased with the use of rFVIIa as would be expected for a more severely injured population (Table 6 ). Overall mortality was greater in those patients receiving rFVIIa (24% vs. 12%, p Ͻ 0.0001), whereas the median time to death occurred later (409 [160 -7817] minutes vs. 172 [60 -2880] minutes, p Ͻ 0.0001; Table 7 ). Patients who were not treated had a greater percentage of deaths (73%, 131 of 180) that occurred in the first 24 hours compared with 58% (69 of 119; p Ͻ 0.03) of patients who were treated with rFVIIa.
Admission vital signs and laboratory values, ISS, GCS score, use of blood components, and use of rFVIIa were significantly different between patients who lived and died. A univariate regression analysis was performed for association with mortality using all significant variables. On multivariate logistic regression, variables associated with mortality included higher ISS, HR, and transfusion of red blood cells and lower blood pressures (SBP and DBP), Hgb concentrations, and GCS score, as well as use of rFVIIa (Table 8) . Using these variables, the calculated ROC was significant (area under the curve, 0.89; 95% CI 0.862-0.915). Use of rFVIIa was independently associated with death. Because use of the laboratory data limited the analysis to 633 patients, a secondary analysis was performed with ISS, GCS score, SBP, and rFVIIa, allowing use of 1,387 patients (68% of the population). The ROC curve was significant (area under the curve, 0.88; 95% CI 0.859 -0.907), and use of rFVIIa was still associated with mortality (OR ϭ 1.668; 95% CI 1.181-2.356). Thus, injury severity, hypotension, and rFVIIa use were independent predictors of mortality and should be considered when matching populations. Because clinical judgment was applied in the use of rFVIIa and this population was more severely injured and in shock, patients were matched based on propensity scoring using the following variables: ISS, GCS score, SBP, DBP, HR, and Hgb concentration. Some laboratory data were not used because they limited the patient population because of missing data. Of the 506 patients treated with rFVIIa, 235 (46%) were successfully matched. After matching, patients treated with rFVIIa received twice as many units of PRBCs (12 [6 -21] units vs. 6 [3] [4] [5] [6] [7] [8] [9] [10] [11] units, p Ͻ 0.0001). Patients treated with rFVIIa also had an increased rate of massive transfusions (34% vs. 63%, p Ͻ 0.0001). Even with these differences, there was no difference in mortality (17% vs. 11%, p ϭ 0.111); however, the incidence of complications increased with the use of rFVIIa (27% vs. 16%, p ϭ 0.005). Because the number of units of PRBC transfused is associated with mortality and complications, it was subsequently included in the propensity score matching analysis. There were 266 (52%) of the patients treated with rFVIIa matched. There were no differences of any clinical consequence between those who received of rFVIIa and those who were not treated with the drug (Table 9 ). There were no significant differences in the rates of mortality (20% vs. 14%, p ϭ 0.08; Table 7 ) or complications (21% vs. 21%, p ϭ 0.88) between rFVIIa treatment and no treatment, respectively.
DISCUSSION
rFVIIa is one of the most studied Food and Drug Administration-approved drugs used off-label for the acute care of the patient who is bleeding. 21, 22 In patients with traumatic injuries, there have been two randomized control trials and multiple single-center observational studies (Hauser et al., submitted for publication). 17, 20 There is, presently, no prospective randomized evidence supporting a decreased mortality or an increase in thromboembolic events with rFVIIa use in patients with traumatic injuries. There are two small studies of combat casualties, which include both military and civilian patients requiring massive transfusions at a single combat support hospital, that suggest a reduction in blood transfusion requirements and 30-day mortality. 23, 24 In this study of the effectiveness of the use of rFVIIa in US military casualties, we found no difference in mortality in a population of patients matched by propensity score.
The rate of complications, specifically those associated with thromboembolic events, has also been a focus point of studies related to the safety of rFVIIa, suggesting a high rate of thromboembolic adverse events after use of rFVIIa; however, comparative populations are not presented. 28, 29 In review of the randomized control trials of various patient populations, the conclusion is that there is no evidence to support an increased complication rate. 21, 22 A review of studies of rFVIIa use in patients with traumatic injuries found no definitive evidence to support a difference in thromboembolic events (Hauser et al., submitted for publication). 20, 24 In this study in the overall population, complications increased with administration of rFVIIa, but when adjusted for increased injury severity, there were no differences.
Horton et al. 15 reported that rFVIIa use in major trauma centers in the United States was related to the volume of trauma patients. The more patients a center treated, the greater the use of rFVIIa. The percentage of trauma admissions using rFVIIa ranged from 0.3% to 1% of admissions. During the period of this study, there were 18,638 records of US military casualties in the JTTR. With this number as the denominator, the rate of use in the military population was 2.7% (511 of 18,638). This rate was notably higher than the rate reported for major civilian centers. This difference may be because of the greater rate of major bleeding in combat casualties, usually reported at two to three times than that in civilian studies. The rate of massive transfusions in patients requiring a transfusion is 11% in the civilian population and 36% in this study of combat casualties. 30 The rate of coagulopathy in combat casualties also increased compared with that of civilian patients. The incidence of coagulopathy (international normalization ratio Ͼ1.5) in this study of combat casualties was 35% in contrast to 25% to 28% reported for civilian populations. [7] [8] [9] In addition, the use of rFVIIa in the military population may have been associated with limited access to blood components, specifically platelets and cryoprecipitate. 18 Thus, the higher rate of use of rFVIIa in the combat casualties seems justified.
In this observational study of the use of rFVIIa in military care facilities during overseas contingency operations, it seems that the physicians selected patients for administration of rFVIIa based on criteria other than those put forth in the clinical practice guideline. Although there are a greater percentage of patients meeting one of the guideline criteria who were treated with rFVIIa, there were more patients (397 vs. 1,072) who met one of the criteria who were not treated. Sixty-nine percent of those patients not treated had one or more criteria positive. Furthermore, more patients received a massive transfusion in the no treatment group (414 vs. 332), suggesting a strong influence of the provider in making a decision to use rFVIIa, based on influencing factors other than the guideline. This is apparent in the initial attempt at propensity score matching, where a marked increase was noted in the use of PRBC in patients treated with rFVIIa. This difference implies that clinicians administered rFVIIa based on bleeding irrespective of physiologic or laboratory data. It also points out the difficulty in differentiating bleeding amenable to treatment with rFVIIa from that requiring surgical intervention. Thus, selection based on bleeding would seem to be a major confounding factor. In the final analysis, taking PRBC transfusion into account, a selection bias is also noted in comparison of the overall analysis with the propensity analysis. There was a reduction in seriousness of injury of patients receiving rFVIIa in the population matched by propensity analysis because the amount of blood components used and the rate of massive transfusions were reduced compared with the overall rFVIIa population. Therefore, those patients requiring the greatest amount of blood components were not able to be matched. The process used by physicians to use select rFVIIa seems to have contributed to the association of rFVIIa with mortality on multifactorial logistic regression because military clinicians were giving rFVIIa to most severely injured patients with major bleeding.
Stein et al. 31 have raised the issue of rFVIIa's use when patients are in extremis and administration of rFVIIa is futile. In this study, patients receiving rFVIIa had a higher ISS and greater incidence of massive transfusion, both of which are associated with poorer outcomes. Furthermore, Stein et al. noted that patients with profound acidosis and hypovolemia predicted failure of rFVIIa. In this study, patients administered rFVIIa at admission had greater base deficit, lower blood pressures, and increased HRs indicative of worse hemorrhagic shock. All of these factors further suggest physician bias based on clinical judgment for use of rFVIIa in the more severely injured bleeding patients.
Observational nonrandomized studies have a role when randomized control trials are not available or feasible as is the case in the combat environment. As expected with an observational study, the present data demonstrated striking differences between treated and untreated patients associated with a major disparity in the severity of injury attributed to physician selection bias. The goal of a propensity analysis is to use observational data to create an analysis that resembles what would have occurred under the optimal conditions of a randomized control trial. 32 We used propensity score matching to compensate for the difference in injury severity. As noted above, this eliminated the more severely injured patients from the treated population and the less-injured patients from the population not treated. Matching using ISS, GCS score, SBP, DBP, HR, Hgb, and sum PRBC administered as indices of injury severity and shock state accomplished the goal of creating uniform populations. There were no clinically significant differences between groups in a wide range of variables after the matching (Table 9 ). After matching, there was no significant difference in mortality or complication rates between treated and untreated patients. However, the trend (p ϭ 0.08) of an increased mortality with rFVIIa should be considered, especially in light of its being independently associated with mortality in a multivariate logistic regression. This difference may again be the result of rFVIIa's being used as a last-ditch effort in massively bleeding patients, as mentioned above, or other unmeasured clinical factors. At present, existing data do not support the empiric use of rFVIIa use in combat casualties. To fully understand the use of rFVIIa, funding agencies must undertake studies validating predictive algorithms that identify patients who could potentially benefit from this drug and other drugs. This must be accomplished before efficacy studies can be undertaken.
Limitations of this study should be noted. This was an observational study with inherent limitations, specifically a lack of randomization of patient assignment, which we attempted to handle by performing a propensity analysis. Another limitation is the lack of information on the time of administration and dose of rFVIIa used. Previous work in combat casualties suggests that administration of rFVIIa early in the course of care is of benefit, whereas other researchers have also demonstrated that administration late as a last-ditch effort is futile. 23, 24, 31, 33 In addition to the improved survival with early rFVIIa use, there was also an increased use of fresh whole blood and cryoprecipitate in the rFVIIa group. The relationship of rFVIIa use with products containing fresh fibrinogen needs to be further investigated. The lack of information in this study on time of administration and the status of the patient at that point is of concern. The recommended dose in the military clinical practice guideline is 90 g/kg to 120 g/kg IV push. We do not know whether this dose was used in this study; however, an earlier study in a combat support hospital found the dose of rFVIIa to be 105 g/kg to 110 g/kg, supporting adherence to the guideline. 23 As the military introduces new and novel devices, drugs and clinical practice guidelines into the care of the combat casualties, it is incumbent to evaluate their effectiveness and safety. This study is such an attempt. Efforts have also been undertaken to evaluate the use of tourniquets, initial burn care resuscitation during evacuation, plasma:platelet:PRBC ratios, and use of fresh whole blood. 5,18,34 -37 These efforts are facilitated by the presence of the JTTR and the in-theater research team. 26 This form of vigilance must continue to be supported, and we must adhere to the highest standards of clinical research within the limitations of the combat environment, or through support of research in civilian institutions.
In military casualties, rFVIIa is used in the most severely injured patients based on physician selection rather than rigid adherence to published guideline criteria. Use of rFVIIa is not associated with an improvement in survival or an increase in complications. The undetected bias of physician selection of patients for treatment with rFVIIa, likely, has an impact on case matching to achieve equivalence similar to that of randomized control studies. This inability to match populations, thus, prevents definitive interpretation of this study and other studies of similar design. This problem emphasizes the need to develop entry criteria to identify patients who would potentially benefit rFVIIa and the need to subsequently perform efficacy studies.
